Cardiovascular Research Advance Access first published online on March 13, 2008
This version [Corrected Proof] published online on April 8, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn071
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins
1 Research Institute for Internal Medicine, Rikshospitalet Medical Center, University of Oslo, Oslo, Norway
2 Section of Clinical Immunology and Infectious Diseases, Rikshospitalet Medical Center, University of Oslo, Sognsvannsveien 20, N-0027 Oslo, Norway
3 Department of Cardiology, Rikshospitalet Medical Center, University of Oslo, Oslo, Norway
* Corresponding author. Tel: +47 23070000; fax: +47 23073630. E-mail address: pal.aukrust{at}rikshospitalet.no
Aims: CXC ligand 16 (CXCL16) may be involved in inflammation and lipid metabolism, and we hypothesized a role for this chemokine in coronary artery disease (CAD).
Methods and results: We performed clinical studies in CAD patients as well as experimental studies in cells with relevance to atherogenesis [i.e. endothelial cells, vascular smooth muscle cells (SMC), and peripheral blood mononuclear cells (PBMC)]. We also examined the ability of HMG-CoA reductase inhibitors (statins) to modulate CXCL16 levels both in vivo and in vitro. Our main findings were: (i) patients with stable (n = 40) and unstable (n = 40) angina had elevated plasma levels of CXCL16 compared with controls (n = 20); (ii) low-dose simvastatin (20 mg qd, n = 15) and high-dose atorvastatin (80 mg qd, n = 9) down-regulated plasma levels of CXCL16 during 6 months of therapy; (iii) in vitro, atorvastatin significantly decreased the interleukin (IL)-1β-mediated release of CXCL16 from PBMC and endothelial cells; (iv) attenuating effect of atorvastatin on the IL-1β-mediated release of CXCL16 in PBMC seems to involve post-transcriptional modulation as well as down-regulation of CXCL16 release through inhibition of the protease a disintegrin and metalloproteinase 10 (ADAM10); (v) soluble CXCL16 increased the release of IL-8, monocyte chemoattractant peptide 1, and matrix metalloproteinases in vascular SMC and increased the release of IL-8 and monocyte chemoattractant peptide 1 in PBMC, with particularly enhancing effects in cells from CAD patients.
Conclusion: Our findings suggest that soluble CXCL16 could be linked to atherogenesis not only as a marker of inflammation, but also as a potential inflammatory mediator.
KEYWORDS Atherosclerosis; Chemokines; Coronary artery disease; Statins
Time for primary review: 16 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. Jansson, P. Aukrust, T. Ueland, C. Smith, T. Omland, M. Hartford, and K. Caidahl Soluble CXCL16 Predicts Long-Term Mortality in Acute Coronary Syndromes Circulation, June 30, 2009; 119(25): 3181 - 3188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Barlic, W. Zhu, and P. M. Murphy Atherogenic Lipids Induce High-Density Lipoprotein Uptake and Cholesterol Efflux in Human Macrophages by Up-Regulating Transmembrane Chemokine CXCL16 without Engaging CXCL16-Dependent Cell Adhesion J. Immunol., June 15, 2009; 182(12): 7928 - 7936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Aukrust, B. Halvorsen, A. Yndestad, T. Ueland, E. Oie, K. Otterdal, L. Gullestad, and J. K. Damas Chemokines and Cardiovascular Risk Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1909 - 1919. [Abstract] [Full Text] [PDF]
|
|